Multicompartmentalized vesosomes containing DOX loaded liposomes and 5FU loaded liposomes for synergistic tumor treatment

Xunan Zhang, Wei Zong, Jialiang Wang, Mingdong Dong, Wenlong Cheng, Tianmeng Sun, Xiaojun Han

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The first priority of drug combination therapy in the treatment of cancer is to achieve enhanced therapeutic efficacy and reduced side effects. The main issue in drug combination therapy is the inscrutable interaction between different drug components. Herein, we developed a multicompartmentalized architecture as a new delivery system. A host liposome encapsulates multiple guest liposomes, where various drug components were loaded into disparate compartments separately. This strategy avoids the interaction among different components before their arrival at the targeting sites and provides the fixed drug combination ratio as needed. Doxorubicin (DOX) and 5-fluorouacil (5FU) loaded smaller liposomes were encapsulated into bigger liposomes with a fixed dose ratio of DOX to 5FU. In vivo tumor growth inhibition by vesosomes was evaluated in HeLa tumor-bearing nude mice, which confirms the enhancement of the delivery system on the synergism of the drug combination.

Original languageEnglish
Pages (from-to)4895-4899
Number of pages5
JournalNew Journal of Chemistry
Volume43
Issue number12
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

Zhang, Xunan ; Zong, Wei ; Wang, Jialiang ; Dong, Mingdong ; Cheng, Wenlong ; Sun, Tianmeng ; Han, Xiaojun. / Multicompartmentalized vesosomes containing DOX loaded liposomes and 5FU loaded liposomes for synergistic tumor treatment. In: New Journal of Chemistry. 2019 ; Vol. 43, No. 12. pp. 4895-4899.
@article{846e07679a0e457f8955fee33e38560c,
title = "Multicompartmentalized vesosomes containing DOX loaded liposomes and 5FU loaded liposomes for synergistic tumor treatment",
abstract = "The first priority of drug combination therapy in the treatment of cancer is to achieve enhanced therapeutic efficacy and reduced side effects. The main issue in drug combination therapy is the inscrutable interaction between different drug components. Herein, we developed a multicompartmentalized architecture as a new delivery system. A host liposome encapsulates multiple guest liposomes, where various drug components were loaded into disparate compartments separately. This strategy avoids the interaction among different components before their arrival at the targeting sites and provides the fixed drug combination ratio as needed. Doxorubicin (DOX) and 5-fluorouacil (5FU) loaded smaller liposomes were encapsulated into bigger liposomes with a fixed dose ratio of DOX to 5FU. In vivo tumor growth inhibition by vesosomes was evaluated in HeLa tumor-bearing nude mice, which confirms the enhancement of the delivery system on the synergism of the drug combination.",
author = "Xunan Zhang and Wei Zong and Jialiang Wang and Mingdong Dong and Wenlong Cheng and Tianmeng Sun and Xiaojun Han",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/c9nj00238c",
language = "English",
volume = "43",
pages = "4895--4899",
journal = "New Journal of Chemistry",
issn = "1144-0546",
publisher = "The Royal Society of Chemistry",
number = "12",

}

Multicompartmentalized vesosomes containing DOX loaded liposomes and 5FU loaded liposomes for synergistic tumor treatment. / Zhang, Xunan; Zong, Wei; Wang, Jialiang; Dong, Mingdong; Cheng, Wenlong; Sun, Tianmeng; Han, Xiaojun.

In: New Journal of Chemistry, Vol. 43, No. 12, 01.01.2019, p. 4895-4899.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Multicompartmentalized vesosomes containing DOX loaded liposomes and 5FU loaded liposomes for synergistic tumor treatment

AU - Zhang, Xunan

AU - Zong, Wei

AU - Wang, Jialiang

AU - Dong, Mingdong

AU - Cheng, Wenlong

AU - Sun, Tianmeng

AU - Han, Xiaojun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The first priority of drug combination therapy in the treatment of cancer is to achieve enhanced therapeutic efficacy and reduced side effects. The main issue in drug combination therapy is the inscrutable interaction between different drug components. Herein, we developed a multicompartmentalized architecture as a new delivery system. A host liposome encapsulates multiple guest liposomes, where various drug components were loaded into disparate compartments separately. This strategy avoids the interaction among different components before their arrival at the targeting sites and provides the fixed drug combination ratio as needed. Doxorubicin (DOX) and 5-fluorouacil (5FU) loaded smaller liposomes were encapsulated into bigger liposomes with a fixed dose ratio of DOX to 5FU. In vivo tumor growth inhibition by vesosomes was evaluated in HeLa tumor-bearing nude mice, which confirms the enhancement of the delivery system on the synergism of the drug combination.

AB - The first priority of drug combination therapy in the treatment of cancer is to achieve enhanced therapeutic efficacy and reduced side effects. The main issue in drug combination therapy is the inscrutable interaction between different drug components. Herein, we developed a multicompartmentalized architecture as a new delivery system. A host liposome encapsulates multiple guest liposomes, where various drug components were loaded into disparate compartments separately. This strategy avoids the interaction among different components before their arrival at the targeting sites and provides the fixed drug combination ratio as needed. Doxorubicin (DOX) and 5-fluorouacil (5FU) loaded smaller liposomes were encapsulated into bigger liposomes with a fixed dose ratio of DOX to 5FU. In vivo tumor growth inhibition by vesosomes was evaluated in HeLa tumor-bearing nude mice, which confirms the enhancement of the delivery system on the synergism of the drug combination.

UR - http://www.scopus.com/inward/record.url?scp=85063227839&partnerID=8YFLogxK

U2 - 10.1039/c9nj00238c

DO - 10.1039/c9nj00238c

M3 - Article

VL - 43

SP - 4895

EP - 4899

JO - New Journal of Chemistry

JF - New Journal of Chemistry

SN - 1144-0546

IS - 12

ER -